Safety of the new macrolide immunomodulators

Seminars in Cutaneous Medicine and Surgery

Volumn 20, Issue 4, 2001, Pages 242-249

  Robinson, N ^a   Singri, P ^a   Gordon, K B ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; IMMUNOMODULATING AGENT; MACROLIDE; PIMECROLIMUS; TACROLIMUS;

ARTICLE; CANCER; CARDIOTOXICITY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; HUMAN; IMMUNOMODULATION; INFECTION; METABOLIC DISORDER; NEPHROTOXICITY; ORGAN TRANSPLANTATION; PATIENT MONITORING; PREGNANCY; SKIN DISEASE; SKIN INFLAMMATION;

EID: 0035211541     PISSN: 10855629     EISSN: None     Source Type: Journal    
DOI: 10.1053/sder.2001.29063     Document Type: Article

References (68)

1. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: A report of the European Tacrolimus Multicenter Renal Study Group
2. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation
3. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection
4. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation
5. Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506
6. Toxicities of tacrolimus and cyclosporin A after allogeneic blood stem cell transplantation
7. FK506 nephrotoxicity
8. Renal histology with varying FK506 blood levels
9. Associations between cyclosporine therapy and interstitial fibrosis in renal allograft biopsies
10. Cellular and molecular mechanisms of cyclosporin nephrotoxicity
11. Cyclosporine nephrotoxicity: Pathophysiology and comparison with FK-506
12. An endothelin-transforming growth factor beta pathway in the nephrotoxicity of immunosuppressive drugs
13. Transforming growth factor-beta in human glomerular injury
14. Improvement of nephrotoxicity, hypertension, and lipid metabolism after conversion of kidney transplant recipients from cyclosporine to tacrolimus
15. Role of steroid dose in hypertension early after liver transplantation with tacrolimus (FK506) and cyclosporine
16. Low-dose tacrolimus (FK506)-based immunosuppressive protocol in living donor renal transplantation
17. Initial experience with FK506 (tacrolimus) in pediatric renal transplant recipients
18. The role of calcium-channel antagonists in solid organ transplantation
19. Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients
20. Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data
21. Non-lymphoid cancer after liver transplantation
22. Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy
23. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children
24. Prevention and preemptive therapy of posttransplant lymphoproliferative disease in pediatric liver recipients
25. One thousand consecutive primary orthotopic liver transplants under FK 506: Survival and adverse events
26. Lipoprotein patterns in renal transplant patients: A comparison between FK 506 and cyclosporine A patients
27. Effects of tacrolimus on hyperlipidemia after successful renal transplantation: A Southeastern Organ Procurement Foundation multicenter clinical study
28. Incidence of new-onset hypercholesterolemia in renal transplant patients treated with FK 506 or cyclosporine
29. A prospective, randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone in renal transplant patients
30. Neurotoxicity of FK 506 in liver transplant recipients
31. Neurologic complications of FK 506
32. Neurotoxicity after orthotopic liver transplantation. A comparison between cyclosporine and FK506
33. FK506-induced neurotoxicity in liver transplantation
34. Persistent cortical blindness after cyclosporine leukoencephalopathy
35. Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study
36. Metabolic effects of FK 506 in patients with severe psoriasis: Short-term follow-up of seven cases
37. Efficacy of FK 506 in the treatment of recalcitrant pyoderma gangrenosum
38. Pregnancy in chronic renal insufficiency and end-stage renal disease
39. National Transplantation Pregnancy Registry: Analysis of pregnancy outcomes in female liver transplant recipients
40. Outcome of twin pregnancy in a renal transplant recipient treated with tacrolimus
41. Successful pregnancies in a combined pancreas and renal allograft recipient and in a renal graft recipient on tacrolimus treatment
42. FK 506 and successful pregnancy in a patient after renal transplantation
43. A case report of pregnancy in renal transplant recipient treated with FK506 (tacrolimus)
44. Liver transplantation under tacrolimus in infants, children, adults, and seniors: Long-term results, survival, and adverse events in 1000 consecutive patients
45. Cyclosporine and tacrolimus in dermatology
46. Cyclosporine consensus conference: With emphasis on the treatment of psoriasis
47. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat
48. Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes
49. Tacrolimus (FK506) metabolite patterns in blood from liver and kidney transplant patients
50. Oral SDZ ASM 981: Safety, pharmacokinetics and efficacy in patients with moderate to severe chronic plaque psoriasis
51. SDZ ASM 981, in contrast to CyA and FK506 does not suppress the primary immune response in murine allergic contact dermatitis
52. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part II, Safety
53. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis
54. Tacrolimus (FK506) ointment for atopic dermatitis: A phase I study in adults and children
55. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children
56. A short-term trial of tacrolimus ointment for atopic dermatitis
57. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome
58. First experience of topical SDZ ASM 981 in children with atopic dermatitis
59. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis
60. Long-term management with SDZ ASM 981 cream 1% of atopic dermatitis in pediatric patients
61. Low blood concentrations of SDZ ASM 981 in infants with extensive atopic dermatitis treated with cream 1%
62. SDZ ASM 981 cream 1% effective in the treatment of pediatric atopic dermatitis: Two 6-week, randomized, double-blind, vehicle-controlled, multicenter studies with 20-week open-label phases
63. New aspects of the mechanism of corticosteroid-induced dermal atrophy
64. Tacrolimus ointment does not affect collagen synthesis: Results of a single-center randomized trial
65. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: A randomized, double-blind controlled study
66. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients
67. The risk of skin cancer in renal transplant recipients in Queensland, Australia. A follow-up study
68. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens